# Ivosidenib (TIBSOVO®) Combined With Azacitidine According to Current SmPC

> **NCT06181734** · — · COMPLETED · sponsor: **iOMEDICO AG** · enrollment: 8 (actual)

## Conditions studied

- Acute Myeloid Leukemia (AML)

## Interventions

- **DRUG:** Ivosidenib

## Key facts

- **NCT ID:** NCT06181734
- **Lead sponsor:** iOMEDICO AG
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-20
- **Primary completion:** 2025-07-30
- **Final completion:** 2025-07-30
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2026-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06181734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06181734, "Ivosidenib (TIBSOVO®) Combined With Azacitidine According to Current SmPC". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06181734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*